Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13501610 | 1.00 | ESR1 (0.32) | ESR1PTGS1PDE4ACACNA1C | |
| Iodide SCHEMBL5235454 | 0.99 | ESR1 (0.32) | ESR1PTGS1PDE4ACACNA1C | |
| SCHEMBL29597347 | 0.94 | ABCC2 (0.31) | — | |
| SCHEMBL304850 | 0.94 | ABCC2 (0.31) | — | |
| SCHEMBL13946392 | 0.93 | ESR1 (0.31) | ESR1PTGS1PDE4ACACNA1C | |
| Iodide SCHEMBL5234153 | 0.91 | ESR1 (0.30) | ESR1PTGS1PDE4ACACNA1C | |
| SCHEMBL13951014 | 0.90 | — | — | |
| Bromide SCHEMBL5234844 | 0.90 | NPSR1 (0.32) | ESR1PTGS1PDE4A | |
| SCHEMBL12809139 | 0.89 | — | — | |
| SCHEMBL13764758 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| US-9409896-B2 | Sustained release pharmaceutical compositions comprising an antibacterial agent | MELINTA THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2124942-B1 | Combination medicaments for treating bacterial infections | BASILEA PHARMACEUTICA AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20160058750-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | MELINTA SUBSIDIARY CORP. | 2016-03-03 | — | — | US | disclosed |
| WO-2014152332-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | MELINTA THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2012061360-A2 | PHARMACEUTICAL COMPOSITIONS | RIB-X PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD (BM) | 2010-11-18 | — | — | US | disclosed |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL, LTD. (BM) | 2010-11-11 | — | — | US | disclosed |
| US-7662841-B2 | Imidazothiazole derivatives and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-20090082571-A1 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | SASAKI TOSHIRO | 2009-03-26 | — | — | US | disclosed |
| US-20090082571-A1 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | SASAKI TOSHIRO | 2009-03-26 | — | — | US | disclosed |
| US-20090036685-A1 | Process for Producing Imidazothiazole Derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| WO-2008085913-A1 | METHODS FOR TREATING, PREVENTING, OR REDUCING THE RISK OF OPTHALMIC, OTIC, AND NASAL INFECTIONS | RIB-X PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167475-A1 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | SASAKI TOSHIRO | 2008-07-10 | — | — | US | disclosed |
| US-20080114164-A1 | Imidazothiazole Derivatives and Process for Producing the Same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080076917-A1 | Intermediates of 2-Substituted Carbapenem Derivatives and Process for Production Thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076917-A1 | Intermediates of 2-Substituted Carbapenem Derivatives and Process for Production Thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-03-27 | — | — | US | disclosed |
| WO-2008020904-A2 | METHOD FOR REDUCING THE RISK OF OR PREVENTING INFECTION DUE TO SURGICAL OR INVASIVE MEDICAL PROCEDURES | RIB-X PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1840129-A1 | IMIDAZOTHIAZOLE DERIVATIVE AND METHOD FOR PRODUCING SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | MGAM, BPGM, MRPL21 | ESR1 4042/4885PTGS1 1825/4885PDE4A 3233/4885 |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | ESR1 2915/4885PTGS1 2156/4885PDE4A 1447/4885 |
| US-20160058750-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | NCEH1, NRDC, LPL | ESR1 3428/4885PTGS1 2799/4885PDE4A 2890/4885 |
| US-20080167475-A1 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | MGAM, G6PD, COASY | ESR1 4035/4885PTGS1 1559/4885PDE4A 1053/4885 |
| US-20080076917-A1 | Intermediates of 2-Substituted Carbapenem Derivatives and Process for Production Thereof | MGAM, G6PD, COASY | ESR1 4035/4885PTGS1 1559/4885PDE4A 1053/4885 |
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | ESR1 2915/4885PTGS1 2156/4885PDE4A 1447/4885 |
| US-20080114164-A1 | Imidazothiazole Derivatives and Process for Producing the Same | MGAM2, OXA1L, CSNK2A2 | ESR1 2517/4885PTGS1 3792/4885PDE4A 4029/4885 |
| US-20090082571-A1 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | MGAM, G6PD, COASY | ESR1 4035/4885PTGS1 1559/4885PDE4A 1053/4885 |
| US-20090036685-A1 | Process for Producing Imidazothiazole Derivatives | NAMPT, NAPRT, NNT | ESR1 4433/4885PTGS1 1905/4885PDE4A 1461/4885 |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | ESR1 2915/4885PTGS1 2156/4885PDE4A 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.